HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Standards – ST.25

STANDARD ST.25

OCTOBER 2009 CHANGES

INTRODUCTION .................................................................................................................................... 1
Footnote, revised October 2009 – SDWG/11.......................................................................................1

ANNEX C................................................................................................................................................ 2
Annex C, revised October 2009 – SDWG/11....................................................................................... 2

Date: December 2009
STANDARD ST.25

STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN PATENT APPLICATIONS

Standard adopted by the PCIPI Executive Coordination Committee, SCIT Standards and Documentation Working Group at its twenty-second eleventh session on May 28, 1998 October 30, 2009

It is recommended that Offices apply the provisions of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” as set out in Annex C to the Administrative Instructions under the PCT, *mutatis mutandis*, to all patent applications other than the PCT international applications, noting that certain provisions specific to PCT procedures and requirements may not be applicable to patent applications other than PCT international applications(*). The text of that PCT Standard is reproduced on the following pages.

(*) If, on July 1, 19982009, the national law and practice applicable by an Office is not compatible with the provisions of the first two sentences of paragraph 3(i) of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” requiring that a sequence listing which is contained in the international application as filed “shall be presented as a separate part of the description, be placed at the end of the application, preferably be entitled ‘Sequence Listing’, begin on a new page and have independent page numbering”, that Office may choose not to follow those provisions for as long as that incompatibility continues.